203 related articles for article (PubMed ID: 37068580)
1. Designed Loop Extension Followed by Combinatorial Screening Confers High Specificity to a Broad Matrix MetalloproteinaseInhibitor.
Bonadio A; Wenig BL; Hockla A; Radisky ES; Shifman JM
J Mol Biol; 2023 Jul; 435(13):168095. PubMed ID: 37068580
[TBL] [Abstract][Full Text] [Related]
2. Development of High Affinity and High Specificity Inhibitors of Matrix Metalloproteinase 14 through Computational Design and Directed Evolution.
Arkadash V; Yosef G; Shirian J; Cohen I; Horev Y; Grossman M; Sagi I; Radisky ES; Shifman JM; Papo N
J Biol Chem; 2017 Feb; 292(8):3481-3495. PubMed ID: 28087697
[TBL] [Abstract][Full Text] [Related]
3. Converting a broad matrix metalloproteinase family inhibitor into a specific inhibitor of MMP-9 and MMP-14.
Shirian J; Arkadash V; Cohen I; Sapir T; Radisky ES; Papo N; Shifman JM
FEBS Lett; 2018 Apr; 592(7):1122-1134. PubMed ID: 29473954
[TBL] [Abstract][Full Text] [Related]
4. Quantitative mapping of binding specificity landscapes for homologous targets by using a high-throughput method.
Aharon L; Aharoni SL; Radisky ES; Papo N
Biochem J; 2020 May; 477(9):1701-1719. PubMed ID: 32296833
[TBL] [Abstract][Full Text] [Related]
5. Affinity- and specificity-enhancing mutations are frequent in multispecific interactions between TIMP2 and MMPs.
Sharabi O; Shirian J; Grossman M; Lebendiker M; Sagi I; Shifman J
PLoS One; 2014; 9(4):e93712. PubMed ID: 24710006
[TBL] [Abstract][Full Text] [Related]
6. Directed evolution of the metalloproteinase inhibitor TIMP-1 reveals that its N- and C-terminal domains cooperate in matrix metalloproteinase recognition.
Raeeszadeh-Sarmazdeh M; Greene KA; Sankaran B; Downey GP; Radisky DC; Radisky ES
J Biol Chem; 2019 Jun; 294(24):9476-9488. PubMed ID: 31040180
[TBL] [Abstract][Full Text] [Related]
7. Engineering of tissue inhibitor of metalloproteinases TIMP-1 for fine discrimination between closely related stromelysins MMP-3 and MMP-10.
Raeeszadeh-Sarmazdeh M; Coban M; Mahajan S; Hockla A; Sankaran B; Downey GP; Radisky DC; Radisky ES
J Biol Chem; 2022 Mar; 298(3):101654. PubMed ID: 35101440
[TBL] [Abstract][Full Text] [Related]
8. Thermodynamic Basis of Selectivity in the Interactions of Tissue Inhibitors of Metalloproteinases N-domains with Matrix Metalloproteinases-1, -3, and -14.
Zou H; Wu Y; Brew K
J Biol Chem; 2016 May; 291(21):11348-58. PubMed ID: 27033700
[TBL] [Abstract][Full Text] [Related]
9. Engineering minimal tissue inhibitors of metalloproteinase targeting MMPs via gene shuffling and yeast surface display.
Hosseini A; Kumar S; Hedin K; Raeeszadeh-Sarmazdeh M
Protein Sci; 2023 Dec; 32(12):e4795. PubMed ID: 37807423
[TBL] [Abstract][Full Text] [Related]
10. Bioorthogonal PEGylation Prolongs the Elimination Half-Life of N-TIMP2 While Retaining MMP Inhibition.
Hayun H; Arkadash V; Sananes A; Arbely E; Stepensky D; Papo N
Bioconjug Chem; 2022 May; 33(5):795-806. PubMed ID: 35446024
[TBL] [Abstract][Full Text] [Related]
11. Identification of highly selective MMP-14 inhibitory Fabs by deep sequencing.
Lopez T; Nam DH; Kaihara E; Mustafa Z; Ge X
Biotechnol Bioeng; 2017 Jun; 114(6):1140-1150. PubMed ID: 28090632
[TBL] [Abstract][Full Text] [Related]
12. Selective function-blocking monoclonal human antibody highlights the important role of membrane type-1 matrix metalloproteinase (MT1-MMP) in metastasis.
Remacle AG; Cieplak P; Nam DH; Shiryaev SA; Ge X; Strongin AY
Oncotarget; 2017 Jan; 8(2):2781-2799. PubMed ID: 27835863
[TBL] [Abstract][Full Text] [Related]
13. Targeting the MMP-14/MMP-2/integrin α
Yosef G; Arkadash V; Papo N
J Biol Chem; 2018 Aug; 293(34):13310-13326. PubMed ID: 29986882
[TBL] [Abstract][Full Text] [Related]
14. Targeting a Designer TIMP-1 to the Cell Surface for Effective MT1-MMP Inhibition: A Potential Role for the Prion Protein in Renal Carcinoma Therapy.
Jiang B; Liu J; Lee MH
Molecules; 2019 Jan; 24(2):. PubMed ID: 30641935
[TBL] [Abstract][Full Text] [Related]
15. Functional mimetic peptide discovery isolated by phage display interacts selectively to fibronectin domain and inhibits gelatinase.
Shoari A; Rasaee MJ; Kanavi MR; Daraei B
J Cell Biochem; 2019 Dec; 120(12):19699-19711. PubMed ID: 31270859
[TBL] [Abstract][Full Text] [Related]
16. An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy.
Xu J; Liu XJ; Li L; Zhang SH; Li Y; Gao RJ; Zhen YS
Oncotarget; 2015 Sep; 6(28):26322-34. PubMed ID: 26314845
[TBL] [Abstract][Full Text] [Related]
17. Utilizing genetic code expansion to modify N-TIMP2 specificity towards MMP-2, MMP-9, and MMP-14.
Hayun H; Coban M; Bhagat AK; Ozer E; Alfonta L; Caulfield TR; Radisky ES; Papo N
Sci Rep; 2023 Mar; 13(1):5186. PubMed ID: 36997589
[TBL] [Abstract][Full Text] [Related]
18. Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase- 7.
Wang LL; Zhang B; Zheng MH; Xie YZ; Wang CJ; Jin JY
Curr Top Med Chem; 2020; 20(27):2459-2471. PubMed ID: 32703131
[TBL] [Abstract][Full Text] [Related]
19. Protein engineering of the tissue inhibitor of metalloproteinase 1 (TIMP-1) inhibitory domain. In search of selective matrix metalloproteinase inhibitors.
Wei S; Chen Y; Chung L; Nagase H; Brew K
J Biol Chem; 2003 Mar; 278(11):9831-4. PubMed ID: 12515831
[TBL] [Abstract][Full Text] [Related]
20. Constraining specificity in the N-domain of tissue inhibitor of metalloproteinases-1; gelatinase-selective inhibitors.
Hamze AB; Wei S; Bahudhanapati H; Kota S; Acharya KR; Brew K
Protein Sci; 2007 Sep; 16(9):1905-13. PubMed ID: 17660250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
